EXHIBIT (A)(1)(V)
                           OFFER TO PURCHASE FOR CASH
                                       BY

                             POLYMEDICA CORPORATION
                                       OF
                   UP TO 4,878,048 SHARES OF ITS COMMON STOCK

                (INCLUDING THE ASSOCIATED STOCK PURCHASE RIGHTS)

   AT A PURCHASE PRICE NOT GREATER THAN $34.50 NOR LESS THAN $30.75 PER SHARE

 THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00
   MIDNIGHT, NEW YORK CITY TIME, ON JUNE 23, 2005, UNLESS THE TENDER OFFER IS
                                   EXTENDED.

                                                                    May 26, 2005

To Brokers, Dealers, Commercial Banks,
Trust Companies and Other Nominees:

     We have been appointed by PolyMedica Corporation, a Massachusetts
corporation ("PolyMedica"), to act as Dealer Manager in connection with its
offer to purchase for cash up to 4,878,048 shares of its common stock $0.01 par
value per share, including the associated stock purchase rights issued under the
Rights Agreement, between PolyMedica and Equiserve Trust Company, dated
September 13, 2002 (the "Shares"), at a price, net to the seller in cash
(subject to applicable withholding of United States Federal, state and local
taxes), without interest, not greater than $34.50 nor less than $30.75 per
Share, specified by such shareholders, upon the terms and subject to the
conditions set forth in the Offer to Purchase dated May 26, 2005 (the "Offer to
Purchase") and the related Letter of Transmittal (which, together with any
supplements or amendments thereto, collectively constitute the "Offer"). Please
furnish copies of the enclosed materials to those of your clients for whom you
hold Shares registered in your name or in the name of your nominee.

     PolyMedica will determine a single per Share price, not greater than $34.50
nor less than $30.75 per Share, that it will pay for the Shares properly
tendered and not properly withdrawn pursuant to the Offer, taking into account
the number of Shares so tendered and the prices specified by tendering
shareholders. PolyMedica will select the lowest purchase price that will allow
it to purchase Shares with an aggregate purchase price of $150 million (or, if
there are not sufficient Shares that are properly tendered and not properly
withdrawn that would yield an aggregate purchase price of $150 million, then all
Shares tendered will be purchased at the highest price specified by the
tendering shareholders). PolyMedica will purchase all Shares validly tendered at
prices at or below the purchase price and not withdrawn upon the terms and
subject to the conditions set forth in the Offer to Purchase and the related
Letter of Transmittal, including the provisions relating to "odd lot" tenders,
proration and conditional tender described in the Offer to Purchase.

     Shares tendered at prices in excess of the purchase price and Shares not
purchased because of proration or conditional tenders will be returned, at
PolyMedica's expense, to the shareholders who tendered such Shares promptly
after the Expiration Date (as defined in the Offer to Purchase). As described in
the Offer to Purchase, in addition to the 4,878,048 Shares subject to the Offer,
PolyMedica may exercise its right to purchase up to an additional 2% of its
outstanding Shares without extending the Offer, subject to applicable legal
requirements. See Section 1 of the Offer to Purchase.


     Enclosed with this letter are copies of the following documents:

     1. Offer to Purchase dated May 26, 2005;

     2. Letter of Transmittal for your use in accepting the Offer and tendering
        Shares and for the information of your clients;

     3. A form of letter that may be sent to your clients for whose account you
        hold Shares in your name or in the name of a nominee, with space
        provided for obtaining such client's instructions with regard to the
        Offer;

     4. Notice of Guaranteed Delivery with respect to Shares; and

     5. Letter to shareholders from the President and Chief Executive Officer of
        PolyMedica.

CERTAIN CONDITIONS TO THE OFFER ARE DESCRIBED IN SECTION 7 OF THE OFFER TO
PURCHASE.

     WE URGE YOU TO CONTACT YOUR CLIENTS AS PROMPTLY AS POSSIBLE. PLEASE NOTE
THAT THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK
CITY TIME, ON JUNE 23, 2005, UNLESS THE OFFER IS EXTENDED.

     In all cases, payment for Shares accepted for payment pursuant to the Offer
will be made only after timely receipt by the Depositary of (1) the certificates
for (or a timely book-entry confirmation (as defined in the Offer to Purchase)
with respect to) such Shares, (2) a Letter of Transmittal (or a facsimile
thereof), properly completed and duly executed, with any required signature
guarantees, or, in the case of a book-entry transfer effected pursuant to the
procedures set forth in Section 3 of the Offer to Purchase, an agent's message
(as defined in the Offer to Purchase), and (3) any other documents required by
the Letter of Transmittal. Accordingly, tendering shareholders may be paid at
different times depending on when certificates for Shares or book-entry
confirmations with respect to Shares are actually received by the depositary.
Under no circumstances will interest be paid on the purchase price of the Shares
regardless of any extension of, or amendment to, the offer or any delay in
paying for such Shares.

     PolyMedica will not pay any fees or commissions to any broker or dealer or
other person (other than the Dealer Manager, Information Agent and the
Depositary, as described in the Offer to Purchase) in connection with the
solicitation of tenders of Shares pursuant to the Offer. However, PolyMedica
will, on request, reimburse you for customary mailing and handling expenses
incurred by you in forwarding copies of the enclosed Offer materials to your
clients. PolyMedica will pay all stock transfer taxes applicable to its purchase
of Shares pursuant to the Offer, subject to instruction 7 of the Letter of
Transmittal.

     Questions and requests for additional copies of the enclosed material may
be directed to the Information Agent at its address and telephone number set
forth on the back cover of the Offer to Purchase.

                                         Very truly yours,

                                         Morgan Stanley & Co.
                                         Incorporated

     NOTHING CONTAINED IN THIS LETTER OR IN THE ENCLOSED DOCUMENTS SHALL RENDER
YOU OR ANY OTHER PERSON THE AGENT OF POLYMEDICA, THE DEPOSITARY, THE DEALER
MANAGER, THE INFORMATION AGENT OR ANY AFFILIATE OF ANY OF THEM OR AUTHORIZE YOU
OR ANY OTHER PERSON TO GIVE ANY INFORMATION OR USE ANY DOCUMENT OR MAKE ANY
STATEMENT ON BEHALF OF ANY OF THEM WITH RESPECT TO THE OFFER OTHER THAN THE
ENCLOSED DOCUMENTS AND THE STATEMENTS CONTAINED THEREIN.

                                        2